Evidence map›Paper›PMID 35806300›Full record

ArticleInternational journal of molecular sciences2022

Different Metabolism and Toxicity of TRANS Fatty Acids, Elaidate and Vaccenate Compared to Cis-Oleate in HepG2 Cells.

Farkas Sarnyai, Éva Kereszturi, Kitti Szirmai, Judit Mátyási, Johanna Iman Al-Hag, Tamás Csizmadia, Péter Lőw, Péter Szelényi, Viola Tamási, Kinga Tibori and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Farkas SarnyaiDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0002-5525-5508
Éva KereszturiDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0003-4778-3332
Kitti SzirmaiDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.
Judit MátyásiDepartment of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.
Johanna Iman Al-HagDepartment of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.
Tamás CsizmadiaDepartment of Anatomy, Cell and Developmental Biology, Eötvös Loránd University, H-1053 Budapest, Hungary.ORCID 0000-0002-2098-9165
Péter LőwDepartment of Anatomy, Cell and Developmental Biology, Eötvös Loránd University, H-1053 Budapest, Hungary.ORCID 0000-0003-2450-7087
Péter SzelényiDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.
Viola TamásiDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.
Kinga TiboriDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0002-6808-4015
Veronika ZámbóDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.
Blanka TóthDepartment of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.
Miklós CsalaDepartment of Molecular Biology, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0002-3829-4361
Semmelweis University · HUBudapest University of Technology and Economics · HUEötvös Loránd University · HU

Funding

Hungarian National Research, Development and Innovation Office FK 138115Hungarian National Research, Development and Innovation Office K 125201Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund TKP2021-EGA-02Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund TKP2021-EGA-24
6 · The paper itself

Abstract

Trans fatty acids (TFAs) are not synthesized in the human body but are generally ingested in substantial amounts. The widespread view that TFAs, particularly those of industrial origin, are unhealthy and contribute to obesity, cardiovascular diseases and diabetes is based mostly on in vivo studies, and the underlying molecular mechanisms remain to be elucidated. Here, we used a hepatoma model of palmitate-induced lipotoxicity to compare the metabolism and effects of the representative industrial and ruminant TFAs, elaidate and vaccenate, respectively, with those of cis-oleate. Cellular FAs, triacylglycerols, diacylglycerols and ceramides were quantitated using chromatography, markers of stress and apoptosis were assessed at mRNA and protein levels, ultrastructural changes were examined by electron microscopy and viability was evaluated by MTT assay. While TFAs were just slightly more damaging than oleate when applied alone, they were remarkably less protective against palmitate toxicity in cotreatments. These differences correlated with their diverse incorporation into the accumulating diacylglycerols and ceramides. Our results provide in vitro evidence for the unfavorable metabolic features and potent stress-inducing character of TFAs in comparison with oleate. These findings strengthen the reasoning against dietary trans fat intake, and they can also help us better understand the molecular mechanisms of lipotoxicity.

Indexed as

Oleic AcidTrans Fatty AcidsCeramidesDiglyceridesFatty AcidsHep G2 CellsHumansOleic AcidsPalmitatesCeramidesDiglycerideselaidic acidFatty AcidsOleic AcidOleic AcidsPalmitatesTrans Fatty Acidscardiovascular diseasesceramidediabetesdiacylglycerolendoplasmic reticulum stresslipotoxicitynon-alcoholic fatty liver diseaseobesitytrans fatty acid

Identifiers

PMID35806300
PMCPMC9266973
OpenAlexW4283737715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.